Comment on Celgene's Run of Bad Luck Continues

Celgene's Run of Bad Luck Continues

Eager to diversify its revenue away from multiple myeloma treatments, Celgene (NASDAQ: CELG) spent $7.2 billion in 2015 to acquire the promising multiple sclerosis drug candidate ozanimod. Then, it rushed ozanimod through phase 3 trials, and submitted it to the FDA.On Tuesday after the closing bell, we learned that Celgene may have moved too quickly.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News